Epilepsy Ireland have written to the Minister for Education and all members of the Oireachtas Joint Committee on Education regarding the outstanding issues surrounding the eligibility criteria for the deferred sitting of the Leaving Cert exams.
Read more about one of our key advocacy issues being highlighted in the Irish Times.
The largest study of its kind has published its results and there is important information for women with epilepsy to be aware of.
Read about the latest Dáil debate on this important ongoing Advocacy campaign.
Epilepsy Ireland have made a submission to the National Centre for Pharmacoeconomics (NCPE) supporting the reimbursement of ONTOZRY® (Cenobamate), in Ireland.
Today is Dravet Syndrome awareness day. While epilepsy is not rare, there are rare subsets of the condition. Dravet Syndrome is one such type of rare epilepsy.
Dravet Syndrome (DS) is a severe type of epilepsy characterised by often prolonged (5+ minute) seizures that usually begin in the first year of life. It affects one in 20,000 – 40,000 people worldwide. It is a genetic condition, often caused by SCN1A gene mutations, most of which are de novo.
There are a number of serious sequences within the new Beyoncé video which could be triggering to people with photosensitive epileps.
A welcome development recently at the recent World Health Assembly. Read more about what has been agreed.
The Patients Deserve Better campaign is set to brief TDs and Senators in Dáil Eireann this week to press the need for investment in Ireland’s neurology nurse specialist capacity.
The campaign has been running since last year and is being coordinated by our colleagues in the Neurological Alliance of Ireland.
Ireland currently has a shortfall of 100 neurology nurses and the campaign is seeking to press Government and policymakers to address this shortfall.
If you experience Focal-Onset seizures and/or have been prescribed the medication ONTOZRY® (Cenobamate), we need your help!